High-purity lyophilized powders, amino acid derivatives, and therapeutic peptide raw materials available for immediate bulk dispatch.
CJC-1295 No DAC, clinically referred to as Modified GRF 1-29 (Mod GRF 1-29), is a synthetic tetrasubstituted 29-amino acid peptide analog of endogenous Growth Hormone-Releasing Hormone (GHRH). Engineered specifically to enhance metabolic stability while preserving physiological pulsatile signaling, CJC-1295 No DAC represents a vital benchmark standard in endocrinological research, peptide manufacturing, and scientific evaluation.
Unlike its long-acting counterpart containing the Drug Affinity Complex (DAC), CJC-1295 Without DAC omits the maleimido-propionic acid linker. This absence ensures that the peptide does not covalently bind to endogenous serum albumin, thereby maintaining a shorter, highly controlled half-life of approximately 30 minutes in physiological models. This distinct profile allows researchers to mimic physiological human growth hormone (hGH) pulses without inducing continuous, non-pulsatile receptor desensitization or chronic IGF-1 elevation.
Key Structural Insight: Mod GRF (1-29) incorporates four key amino acid substitutions relative to native GHRH (1-29): D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27. These specific modifications protect the core sequence against rapid enzymatic cleavage by Dipeptidyl Peptidase IV (DPP-IV), dramatically elevating its chemical integrity in solution.
| Parameter | Specification Standard | Analytical Method |
|---|---|---|
| Chemical Formula | C152H252N44O42 | Mass Spectrometry (MS-ESI) |
| Molecular Weight | 3367.97 g/mol | Calculated vs. Found MS |
| Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 | Edman Degradation / MS Sequencing |
| Purity Level | ≥99.0% (HPLC Area Peak) | RP-HPLC (C18 Column) |
| Physical State | Sterile Lyophilized Powder (White to off-white) | Visual Inspection |
| Unit Packaging | 5mg per Vial (Borosilicate Glass Vial Type I) | Gravimetric Weight Control |
| Endotoxin Content | <0.01 EU/mg | LAL Kinetic Chromogenic Test |
| Counter-Ion | Acetate (TFA exchange available upon bulk request) | Ion Chromatography |
Commercial production of high-grade CJC-1295 No DAC 5mg requires precise adherence to advanced Solid-Phase Peptide Synthesis (SPPS) protocols under cGMP conditions. The complex 29-amino acid sequence demands strict control over coupling efficiency, steric hindrance mitigation, and racemization control.
When procuring GHRH analogs for research applications or retail distribution, understanding the pharmacokinetic differentiation between DAC and No DAC variants is vital for sourcing strategies:
Creating global opportunities by connecting research institutions and pharmaceutical brands with guaranteed product quality and supply chain efficiency.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
An overall factory construction area of 250,000 square meters under international standard allows us to offer flexible, scalable, and cost-effective solutions for clients globally.
The global demand for high-purity peptides like CJC-1295 No DAC 5mg requires manufacturing partners capable of delivering uncompromised quality while maintaining robust batch-to-batch consistency and competitive production costs. Gentolex leverages China's advanced chemical manufacturing ecosystem to provide superior strategic procurement value.
Gentolex offers full-spectrum OEM and ODM services for research chemical distributors, peptide brands, and institutional procurement agents:
As global life sciences research shifts toward targeted endocrine therapies and metabolic regulation models, CJC-1295 No DAC continues to hold a prominent position in specialized application fields.
Gentolex remains committed to advancing synthesis automation and green chemical processing. Our strategic technical objectives include:
High-standard production plants and comprehensive supply chain solutions tailored for international clients.
Explore our latest research updates, product monograph releases, and peptide industry analyses.
Clear answers to technical, commercial, and shipping queries for prospective B2B purchasers and laboratory managers.
Browse related high-purity peptides, endocrine regulatory compounds, and custom synthesized reagents.
